Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma

IMPORTANCE: Targeted therapies for advanced renal cell carcinoma (RCC) have shown increased tolerability and survival advantages over older treatments in clinical trials, but understanding of real-world survival improvements is still emerging. OBJECTIVE: To compare overall and RCC-specific survival...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Netw Open
Egile Nagusiak: Li, Pengxiang, Jahnke, Jordan, Pettit, Amy R., Wong, Yu-Ning, Doshi, Jalpa A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2019
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6575152/
https://ncbi.nlm.nih.gov/pubmed/31199450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.5806
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak